513 related articles for article (PubMed ID: 33666253)
1. In vitro activity of itraconazole against SARS-CoV-2.
Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
[TBL] [Abstract][Full Text] [Related]
2. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
3. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
[TBL] [Abstract][Full Text] [Related]
5. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro.
Zhou Y; Gammeltoft KA; Galli A; Offersgaard A; Fahnøe U; Ramirez S; Bukh J; Gottwein JM
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696509
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effects of human placenta hydrolysate (Laennec
Kim EH; Kim YI; Jang SG; Im M; Jeong K; Choi YK; Han HJ
J Microbiol; 2021 Nov; 59(11):1056-1062. PubMed ID: 34613605
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
13. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
Schloer S; Brunotte L; Mecate-Zambrano A; Zheng S; Tang J; Ludwig S; Rescher U
Br J Pharmacol; 2021 Jun; 178(11):2339-2350. PubMed ID: 33825201
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
Raymonda MH; Ciesla JH; Monaghan M; Leach J; Asantewaa G; Smorodintsev-Schiller LA; Lutz MM; Schafer XL; Takimoto T; Dewhurst S; Munger J; Harris IS
Virology; 2022 Jan; 566():60-68. PubMed ID: 34871905
[TBL] [Abstract][Full Text] [Related]
15. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.
Bakovic A; Risner K; Bhalla N; Alem F; Chang TL; Weston WK; Harness JA; Narayanan A
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572467
[TBL] [Abstract][Full Text] [Related]
16. The
Urda L; Kreuter MH; Drewe J; Boonen G; Butterweck V; Klimkait T
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062310
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
[TBL] [Abstract][Full Text] [Related]
19. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Hattori SI; Higashi-Kuwata N; Hayashi H; Allu SR; Raghavaiah J; Bulut H; Das D; Anson BJ; Lendy EK; Takamatsu Y; Takamune N; Kishimoto N; Murayama K; Hasegawa K; Li M; Davis DA; Kodama EN; Yarchoan R; Wlodawer A; Misumi S; Mesecar AD; Ghosh AK; Mitsuya H
Nat Commun; 2021 Jan; 12(1):668. PubMed ID: 33510133
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
